Bayer to offload Alzheimer’s imaging agent as part of reshuffle?
This article was originally published in Clinica
Executive Summary
Bayer HealthCare is reportedly looking to sell its investigational Alzheimer’s imaging agent florbetaben, as part of efforts to restructure its contrast agent and diagnostics businesses. According to German newspaper Financial Times Deutschland, the company plans to create a new subunit combining its contrast agents with its imaging subsidiary Medrad, which develops devices to diagnose and treat cardiovascular diseases.